Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will require the use of FDA-approved interferon gamma release assays for tuberculosis screening. The CDC plans for the changes to medical screening guidelines to go into effect Oct. 1.
April 2018—Meridian Life Science added Zero-X-React Zika Envelope Rec-Antigen to its line of infectious diseases antigens and antibodies. Suitable for use in ELISA and lateral flow assays, this recombinant Zika envelope antigen is designed to eliminate cross-reactivity of the major conserved domain of all flaviviruses and reacts with IgG and IgM antibodies.
April 2018—Eli Lilly announced the FDA has approved Verzenio (abemaciclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
April 2018—ElitechGroup Molecular Diagnostics launched its Respiratory Bacterial Elite MGB Panel, a high-performance multiplex assay for the diagnosis of bacterial respiratory infections validated on the Elite InGenius sample-to-result system. The panel detects and differentiates in a single reaction M. pneumoniae, C. pneumoniae, and L. pneumophila.
April 2018—Mesa Biotech announced its Accula Flu A/Flu B test is FDA 510(k) cleared and CLIA waived. It is the company’s first flu A/flu B test cassette available in the U.S. The PCR test provides results in approximately 30 minutes. It will be marketed by Sekisui Diagnostics under the Silaris brand.
April 2018—Sciex Diagnostics announced the launch of the Citrine Triple Quad MS/MS and Citrine Qtrap MS/MS systems for clinical diagnostics. The Citrine MS/MS system enables the measurement of trace levels of biomarkers and metabolites at sub-pg/mL concentrations, comprehensive multianalyte panels, and the measurement of large and small molecules.
April 2018—Roche will acquire San Diego–based Ignyta for $27.00 per share in cash, or $1.7 billion. Ignyta, which will continue its operations in San Diego, focuses on precision medicine in oncology aiming to test, identify, and treat patients with cancers harboring specific rare mutations.
April 2018—LGC Maine Standards announced it has enhanced the Validate THY linearity and calibration verification kit by adding free triiodothyronine (FT3) as a component of total triiodothyronine (TT3).
April 2018—One year after its establishment, the Blood Profiling Atlas in Cancer consortium announced the public release of an initial dataset aimed at speeding the development and approval of liquid biopsy technologies. The dataset resides in the BloodPAC data commons and was developed to deepen the understanding of a patient’s cancer and accelerate the development of liquid biopsy technology to improve the outcomes of patients with cancer.
April 2018—Advanced Instruments announced the availability of its Osmo1 Single-Sample Micro-Osmometer. It is suited for clinical laboratories that directly draw and test small sample volumes and was designed specifically to improve efficiency and reduce sample turnaround time.
